Iga Świątek, the Polish tennis star, has accepted a one-month suspension after testing positive for trimetazidine, a banned substance.

The International Tennis Integrity Agency (ITIA) announced the suspension on Thursday, stating that Świątek's level of fault was considered to be at the lowest end of the range for 'No Significant Fault or Negligence.'

What happened?

The ITIA found that Świątek's positive test was caused by the contamination of a regulated non-prescription medication, melatonin, which she had been taking for jet lag and sleep issues.

The medication was manufactured and sold in Poland, and the ITIA accepted that the violation was not intentional.

Why it matters for Iga Świątek

Świątek, a five-time Grand Slam winner, will forfeit prize money from the Cincinnati Open and has already missed three tournaments due to her provisional suspension from September 22 to October 4.

The 23-year-old tennis player said she was shocked by the positive test and had instantly cooperated with the ITIA to run tests on her nutritional supplements and medications.

What comes next?

The Women's Tennis Association (WTA) has expressed its support for Świątek, stating that she has consistently demonstrated a strong commitment to fair play and upholding the principles of clean sport.

The WTA emphasized that athletes must take every precaution to verify the safety and compliance of all products they use, as even unintentional exposure to prohibited substances can have significant consequences.

Świątek has won four French Open titles in her career and is currently ranked No. 2 in the world.

The World Anti-Doping Agency (WADA) will review the ITIA's decision and reserves the right to take an appeal to the Court of Arbitration for Sport.

Świątek concluded a video posted to social media by asking her fans to continue to support her during this difficult time.

The suspension will last for one month, and Świątek will be eligible to return to competition on a date to be determined.

The ITIA's decision is a reminder of the importance of strict adherence to anti-doping regulations in tennis.

Świątek's case highlights the challenges athletes face in navigating the use of medications and supplements.

The Polish tennis star has been open about her struggles with sleep and jet lag, and her use of melatonin was intended to help her manage these issues.

However, the contamination of the medication led to the positive test, and Świątek has accepted the consequences.

The WTA's support for Świątek is a testament to her commitment to clean sport and fair play.

The organization emphasized that athletes must be vigilant in ensuring the safety and compliance of all products they use.

Świątek's suspension is a setback for the tennis star, but she is expected to bounce back strong.

The Polish tennis star has a strong record of competing at the highest level and is expected to continue to be a major force in women's tennis.

The ITIA's decision is a reminder that even unintentional violations of anti-doping regulations can have significant consequences.

Świątek's case serves as a warning to all athletes to be cautious when using medications and supplements.

The World Anti-Doping Agency (WADA) will continue to monitor the situation and ensure that all athletes are held to the same standards.

The tennis world will be watching Świątek's return to competition closely, and she is expected to come back strong.

The Polish tennis star has a lot to prove, and her fans are eagerly awaiting her return to the court.